Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 9/20 | 0.53 |
| ▸ | CA2 | P00918 | 9/20 | 0.53 |
| ▸ | CA12 | O43570 | 6/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020260 | 0.96 | TDP1 (0.70) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL30352623 | 0.94 | MEN1 (0.60) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL25801555 | 0.94 | TDP1 (0.73) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL9531926 | 0.94 | TDP1 (0.73) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL31181380 | 0.93 | MAOA (0.62) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL8821237 | 0.93 | MAOA (0.62) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL20425056 | 0.93 | MAOA (0.62) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL1760969 | 0.92 | MEN1 (0.59) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL569251 | 0.92 | TDP1 (0.74) | MEN1GAAKMT2ATDP1MAOA | |
| SCHEMBL25354781 | 0.91 | MAOA (0.65) | MEN1GAAKMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118829423-A | Compositions for delivery of payload molecules to airway epithelium | 摩登纳特斯有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-116348147-A | Compositions for delivery of payload molecules to airway epithelium | 摩登纳特斯有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-111295368-A | Chemically activated water soluble prodrugs | 大日本住友制药株式会社 | 2020-06-16 | — | — | CN | disclosed |
| EP-2894149-B1 | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| EP-1339686-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2015-09-16 | — | — | EP | disclosed |
| EP-2894149-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2015-07-15 | — | — | EP | disclosed |
| EP-1339686-A2 | CYANOGUANIDINE PRODRUGS | Leo Pharma A/S (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-6525077-B2 | Antiproliferative agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-02-25 | — | — | US | disclosed |
| US-20020165201-A1 | Cyanoguanidine prodrugs | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-11-07 | — | — | US | disclosed |
| WO-2002042265-A2 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165201-A1 | Cyanoguanidine prodrugs | CBR1, SIGMAR1, ROR1 | MEN1 4379/4885GAA 4017/4885KMT2A 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.